Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer.
Phase 1
- Conditions
- Advanced metastatic colorectal cancers
- Registration Number
- JPRN-UMIN000007801
- Lead Sponsor
- Kinki University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnant Lactation Prognosis >= 3 months Active infectious disease Systemic use of steroid hormones or immunosuppressive drugs. Others (Doctors judges)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safty Immunological response (in vitro CTL induction)
- Secondary Outcome Measures
Name Time Method Progression free survival Overall survival Data related to tumor regression Tumor marker (CEA) profile